0001213900-24-014996.txt : 20240216
0001213900-24-014996.hdr.sgml : 20240216
20240216180211
ACCESSION NUMBER: 0001213900-24-014996
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reich Kristian
CENTRAL INDEX KEY: 0001920553
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39630
FILM NUMBER: 24649902
MAIL ADDRESS:
STREET 1: DORFSTRASSE 29
CITY: ZUG
STATE: V8
ZIP: 6300
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MoonLake Immunotherapeutics
CENTRAL INDEX KEY: 0001821586
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: DORFSTRASSE 29
CITY: ZUG
STATE: V8
ZIP: 6300
BUSINESS PHONE: 41 41 510 8022
MAIL ADDRESS:
STREET 1: DORFSTRASSE 29
CITY: ZUG
STATE: V8
ZIP: 6300
FORMER COMPANY:
FORMER CONFORMED NAME: Helix Acquisition Corp
DATE OF NAME CHANGE: 20200818
4
1
ownership.xml
X0508
4
2024-02-14
0
0001821586
MoonLake Immunotherapeutics
MLTX
0001920553
Reich Kristian
C/O MOONLAKE IMMUNOTHERAPEUTICS
DORFSTRASSE 29
ZUG
V8
6300
SWITZERLAND
0
1
0
0
Chief Scientific Officer
1
Class A ordinary shares, par value $0.0001 per share
2024-02-14
4
S
0
10000
62.42
D
3017483
I
See footnote.
Class A ordinary shares, par value $0.0001 per share
2024-02-14
4
S
0
10000
62.43
D
130071
D
Class A ordinary shares, par value $0.0001 per share
2024-02-15
4
S
0
10000
60.17
D
3007483
I
See footnote.
Class A ordinary shares, par value $0.0001 per share
2024-02-15
4
S
0
10000
60.16
D
120071
D
Class A ordinary shares, par value $0.0001 per share
2024-02-16
4
S
0
10000
60.15
D
2997483
I
See footnote.
Class A ordinary shares, par value $0.0001 per share
2024-02-16
4
S
0
10000
60.15
D
110071
D
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.10 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.18 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich
2024-02-16